Trial reportAsian Pacific journal of cancer prevention : APJCP2025
Phase II Study to Evaluate the Safety and Efficacy of Neoadjuvant Chemotherapy with Weekly Paclitaxel and Carboplatin Followed by Radical Chemoradiation in Locally Advanced Cervical Cancer in Egyptian Population.
Trial report in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Licoricidin Enhances Paclitaxel-induced Apoptosis Through Endoplasmic Reticulum Stress in Human Cervical Cancer Cells.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince 1999, platinum based chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer patients, but the estimated increase in overall survival (OS) over a 5-year period was only 6% in patients treated with CRT versus radiotherapy alone.There have been no additional developments in the treatment of locally advanced cervical cancer(LACC) patients since CRT introduction and approximately 30-40% of those patients failed to achieve complete response to CRT. Therefore, alternative approaches are needed to improve the outcome for such patients. NACT with Weekly paclitaxel and carboplatin for 4 - 6 weeks as dose-dense chemotherapy prior to CRT could be one such potential approach.
methodsA phase II, prospective , non randomized study was conducted at the Clinical Oncology Department of Ain Shams University hospital. 42 patients diagnosed with locally advanced cervical cancer patients (FIGO 2018 stage IIB to IVA ) and were treated by NACT carboplatin (AUC2) and paclitaxel (80 mg/m 2) for 4 - 6 week, then they proceeded to definitive CCRT (with a dose of 45-50.4 Gy) with weekly cisplatin followed by brachytherapy. Response rate and toxicity were the primary endpoints and Survival were the secondary endpoints.
resultsMedian age at diagnosis - 48 years ; 90% (38/42 ) of cases diagnosed with squamous cell carcinoma and 9% (4/42) diagnosed with other histologies; 38% (16/42) had FIGO stage IIB , 40% (17/42) with stage IIIC, 7% (3/42) stage IIIB, 7% (3/42) with stage IVA, 5% (2 /42) with stage 2A and only 1 case diagnosed with stage 3A. 42 patients were evaluated.The overall response rate post-NACT was 71% and 61% developed complete response rate (CR) at end of all treatment course. Grade 3and 4 adverse events during NACT were most common, with hematological toxicity occurring in 21% of patients. There were no treatment- related deaths. The 9-month and 12-month overall survival rates were 94% and 84% , respectively.
conclusionNACT with dose dense protocol, followed by CCRT, is a treatment option for locally advanced cervical cancer with controllable adverse events and agood response rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.